Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice.

Abstract

To investigate the efficacy and safety of gatifloxacin (400mg/day) on chronic prostatitis or cystitis, 453 patients with prostatitis (NIH category II or IIIa) (N=149, mean 45.8+/-13.3 years) and cystitis (N=304, mean 53.8+/-14.3 years) were enrolled. Total NIH CPSI score and symptom score for cystitis decreased from 20.3 to 9.9 (response rate 86.7%, 95% CI 80.2-93.2%) and from 6.2 to 1.8 (response rate 83.2%, 95% CI 78.7-87.7%), respectively. In the overall clinical efficacy, 71.2% and 88.4% of the patients with prostatitis and cystitis were responders, respectively. Of the patients, 15.7% reported insignificant adverse events. These results suggest that gatifloxacin was well tolerated and improved the clinical outcomes in patients with chronic prostatitis or cystitis.

• Authors: Sang Don Lee, Seung Ju Lee, Tae Kon Hwang, Duck Ki Yoon, Kyu Sung Lee, Luck Hee Sung, Myung Soo Choo, Bong Suk Shim, In Rae Cho, Min Eui Kim, Soo Bang Ryu, Chul Sung Kim, Young Gon Kim, Chun Il Kim, Hyun Yul Rhew, Myung Hoon Kim, Yong-Hyun Cho
• Journal: International journal of antimicrobial agents (Int J Antimicrob Agents) Vol. 28 Suppl 1 Pg. S108-12 (Aug 2006) ISSN: 0924-8579 [Print] Netherlands
• PMID: 16844352 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Fluoroquinolones
• Gatifloxacin

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Cystitis (drug therapy, microbiology)
• Female
• Fluoroquinolones (adverse effects, therapeutic use)
• Gatifloxacin
• Humans
• Korea
• Male
• Middle Aged
• Practice Patterns, Physicians'
• Prostatitis (drug therapy, microbiology)